TrueMark Investments LLC Buys New Shares in Natera, Inc. (NASDAQ:NTRA)

TrueMark Investments LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,036 shares of the medical research company's stock, valued at approximately $854,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the last quarter. Norges Bank acquired a new position in shares of Natera in the 4th quarter valued at $224,040,000. Raymond James Financial Inc. acquired a new position in shares of Natera in the 4th quarter valued at $146,419,000. Finally, Vanguard Group Inc. increased its stake in Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after purchasing an additional 879,463 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Trading Up 0.5%

NTRA opened at $171.86 on Monday. The stock has a fifty day moving average price of $157.00 and a 200 day moving average price of $158.46. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The stock has a market cap of $23.47 billion, a price-to-earnings ratio of -116.91 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm's revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.56) EPS. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the transaction, the director now owns 9,704 shares of the company's stock, valued at approximately $1,366,129.12. The trade was a 29.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 9,563 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the transaction, the chief executive officer now directly owns 212,541 shares of the company's stock, valued at $29,417,799.81. This represents a 4.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,755 shares of company stock worth $8,898,589. 7.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Royal Bank Of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. Robert W. Baird boosted their price target on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Morgan Stanley upped their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Piper Sandler boosted their target price on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.